Angiogenesis inhibitors seem to be able to provide the changes needed and their combination with ICIs could, eventually, re-integrate immunotherapy in the treatment strategy of EGFR mutated NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.